Polar Capital Holdings’s Y-mAbs Therapeutics YMAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1,789,800
| Closed | -$8.07M | – | 301 |
|
|
2025
Q2 | $8.07M | Sell |
1,789,800
-41,200
| -2% | -$185K | 0.04% | 209 |
|
|
2025
Q1 | $8.11M | Hold |
1,831,000
| – | – | 0.05% | 203 |
|
|
2024
Q4 | $14.3M | Hold |
1,831,000
| – | – | 0.08% | 170 |
|
|
2024
Q3 | $24.1M | Hold |
1,831,000
| – | – | 0.11% | 129 |
|
|
2024
Q2 | $22.1M | Hold |
1,831,000
| – | – | 0.13% | 124 |
|
|
2024
Q1 | $29.8M | Sell |
1,831,000
-225,872
| -11% | -$3.04M | 0.16% | 118 |
|
|
2023
Q4 | $14M | Sell |
2,056,872
-46,426
| -2% | -$269K | 0.09% | 160 |
|
|
2023
Q3 | $11.5M | Hold |
2,103,298
| – | – | 0.08% | 175 |
|
|
2023
Q2 | $14.3M | Buy |
2,103,298
+111,369
| +6% | +$835K | 0.07% | 173 |
|
|
2023
Q1 | $9.98M | Hold |
1,991,929
| – | – | 0.06% | 188 |
|
|
2022
Q4 | $9.72M | Sell |
1,991,929
-539,617
| -21% | -$3.92M | 0.08% | 194 |
|
|
2022
Q3 | $36.5K | Sell |
2,531,546
-421,125
| -14% | -$6.97M | 0.23% | 95 |
|
|
2022
Q2 | $44.7K | Buy |
2,952,671
+75,000
| +3% | +$875K | 0.26% | 84 |
|
|
2022
Q1 | $34.2K | Buy |
2,877,671
+1,500,000
| +109% | +$15.4M | 0.15% | 119 |
|
|
2021
Q4 | $22.3K | Buy |
1,377,671
+222,710
| +19% | +$4.76M | 0.08% | 162 |
|
|
2021
Q3 | $33K | Buy |
1,154,961
+569,040
| +97% | +$17.9M | 0.13% | 133 |
|
|
2021
Q2 | $19.8K | Buy |
585,921
+577,892
| +7,198% | +$18.5M | 0.09% | 168 |
|
|
2021
Q1 | $243K | Sell |
8,029
-499,604
| -98% | -$20.5M | ﹤0.01% | 319 |
|
|
2020
Q4 | $25.1M | Buy |
+507,633
| New | +$23.5M | 0.15% | 132 |
|
Other funds holding YMAB
Polar Capital Holdings's YMAB Position: Q3 2025 in Review
Polar Capital Holdings sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 1,789,800 shares — an estimated $8.07M sold.
Polar Capital Holdings first reported a position in YMAB in Q4 2020 and held it in 19 quarters. The position peaked at $29.8M in Q1 2024. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.
- Polar Capital Holdings reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
- Polar Capital Holdings sold 1,789,800 Y-mAbs Therapeutics shares in Q3 2025, an estimated $8.07M.
- Polar Capital Holdings first reported a position in Y-mAbs Therapeutics in Q4 2020 and held it in 19 quarters.
- Polar Capital Holdings's Y-mAbs Therapeutics position peaked at $29.8M in Q1 2024.
- 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.
Based on Polar Capital Holdings's 13F filing for Q3 2025, filed 14 Nov 2025.